Vifor Pharma Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vifor Pharma Group
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Becoming a first-time CEO of a biotech company in 2020 meant dealing with unexpected challenges without any instruction book to follow. Santhera Pharmaceuticals’ Dario Eklund not only had COVID-19 upheaval to manage, but also a late-stage trial failure, a virtual financing and a new plan for the company to sell to stakeholders.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
- Galenica Group
- Relypsa, Inc.
- Vifor Pharma
- Vifor-Fresenius Medical Care Renal Pharma Ltd.
- OM Pharma